Clinical Trials Browser

Phase 3 × INDUSTRY × Melphalan × Clear all

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Multiple Myeloma

NCT03217812 2024-04-25

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Phase 3 Completed

Multiple Myeloma

NCT02678572 2023-12-21

FOCUS

Phase 3 Completed

102 enrolled 1 FDA

Uveal Melanoma

NCT05022901 2023-12-21

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Phase 3 Unknown

Uveal Melanoma

NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Phase 3 Completed

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT00689936 2019-11-20

FIRST

Phase 3 Completed

1,623 enrolled 56 charts

Multiple Myeloma

NCT01818752 2019-08-26

CLARION

Phase 3 Completed

955 enrolled 20 charts

Multiple Myeloma

NCT00507416 2014-05-01

UPFRONT

Phase 3 Completed

502 enrolled 17 charts

Multiple Myeloma